Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 298

1.

Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.

Pugliese MS, Karam AK, Hsu M, Stempel MM, Patil SM, Ho AY, Traina TA, Van Zee KJ, Cody HS 3rd, Morrow M, Gemignani ML.

Ann Surg Oncol. 2010 Apr;17(4):1063-8. doi: 10.1245/s10434-009-0834-5. Epub 2009 Dec 22.

PMID:
20033325
[PubMed - indexed for MEDLINE]
2.

Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.

Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J, Rogers K, Arnold B, Eaton A, Catalano J, McCormick B, Powell S, Ho A.

Ann Surg Oncol. 2012 Nov;19(12):3762-70. doi: 10.1245/s10434-012-2386-3. Epub 2012 May 11.

PMID:
22576064
[PubMed - indexed for MEDLINE]
3.

Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.

Pernas S, Gil M, Benítez A, Bajen MT, Climent F, Pla MJ, Benito E, Guma A, Gutierrez C, Pisa A, Urruticoechea A, Pérez J, Gil Gil M.

Ann Surg Oncol. 2010 Mar;17(3):772-7.

PMID:
20183912
[PubMed - indexed for MEDLINE]
4.

The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.

Fan YG, Tan YY, Wu CT, Treseler P, Lu Y, Chan CW, Hwang S, Ewing C, Esserman L, Morita E, Leong SP.

Ann Surg Oncol. 2005 Sep;12(9):705-11. Epub 2005 Aug 4. Erratum in: Ann Surg Oncol. 2005 Nov;12(11):952.

PMID:
16079953
[PubMed - indexed for MEDLINE]
5.

Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.

Kiluk JV, Ly QP, Santillan AA, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE.

Ann Surg Oncol. 2010 Feb;17(2):552-7. doi: 10.1245/s10434-009-0800-2.

PMID:
19957043
[PubMed - indexed for MEDLINE]
6.

Factors predicting the non-sentinel lymph node involvement in breast cancer patients with sentinel lymph node metastases.

Boler DE, Uras C, Ince U, Cabioglu N.

Breast. 2012 Aug;21(4):518-23. doi: 10.1016/j.breast.2012.02.012. Epub 2012 Mar 10.

PMID:
22410110
[PubMed - indexed for MEDLINE]
7.

Memorial Sloan-Kettering Cancer Center Nomogram to predict the risk of non-sentinel lymph node metastasis in Japanese breast cancer patients.

Sasada T, Murakami S, Kataoka T, Ohara M, Ozaki S, Okada M, Ohdan H.

Surg Today. 2012 Feb;42(3):245-9. doi: 10.1007/s00595-011-0088-2. Epub 2011 Dec 14.

PMID:
22167482
[PubMed - indexed for MEDLINE]
8.

Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy.

Langer I, Marti WR, Guller U, Moch H, Harder F, Oertli D, Zuber M.

Ann Surg. 2005 Jan;241(1):152-8.

PMID:
15622003
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.

Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M.

Ann Surg Oncol. 2009 Dec;16(12):3366-74. doi: 10.1245/s10434-009-0660-9. Epub 2009 Sep 4.

PMID:
19760047
[PubMed - indexed for MEDLINE]
10.

Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes.

Guenther JM, Hansen NM, DiFronzo LA, Giuliano AE, Collins JC, Grube BL, O'Connell TX.

Arch Surg. 2003 Jan;138(1):52-6.

PMID:
12511150
[PubMed - indexed for MEDLINE]
11.

Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.

Torrenga H, Fabry H, van der Sijp JR, van Diest PJ, Pijpers R, Meijer S.

J Surg Oncol. 2004 Oct 1;88(1):4-7; discussion 7-8.

PMID:
15384064
[PubMed - indexed for MEDLINE]
12.

Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients.

Montemurro F, Maggiorotto F, Valabrega G, Kubatzki F, Rossi V, Magistris A, Marocco F, Gatti M, Sarotto I, Aglietta M, Ponzone R.

Ann Surg Oncol. 2012 Nov;19(12):3755-61. doi: 10.1245/s10434-012-2505-1. Epub 2012 Jul 18.

PMID:
22805871
[PubMed - indexed for MEDLINE]
13.

Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer.

Choi SH, Barsky SH, Chang HR.

Breast J. 2003 May-Jun;9(3):153-62.

PMID:
12752622
[PubMed - indexed for MEDLINE]
14.

Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.

Goyal A, Newcombe RG, Chhabra A, Mansel RE.

Ann Surg Oncol. 2008 Jan;15(1):262-7. Epub 2007 Sep 19.

PMID:
17879117
[PubMed - indexed for MEDLINE]
15.

The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures.

Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, Port E, Sacchini V, Sclafani L, VanZee K, Wagman R, Borgen PI, Cody HS 3rd.

Ann Surg. 2004 Sep;240(3):462-8; discussion 468-71.

PMID:
15319717
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Sentinel node mapping for breast cancer: the operative experience of a breast surgeon in a rural community.

Davit FE, Gatmaitan P, Garguilo G.

Am Surg. 2008 May;74(5):423-7.

PMID:
18481500
[PubMed - indexed for MEDLINE]
17.

Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study.

Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L.

J Am Coll Surg. 2009 Mar;208(3):333-40. doi: 10.1016/j.jamcollsurg.2008.10.036. Epub 2008 Dec 25.

PMID:
19317993
[PubMed - indexed for MEDLINE]
18.

Predicting the likelihood of additional nodal metastases in breast carcinoma patients with positive sentinel node biopsy.

Mustać E, Matusan-Ilijas K, Marijić B, Smokvina M, Jonjić N.

Int J Surg Pathol. 2010 Feb;18(1):36-41. doi: 10.1177/1066896909332113. Epub 2009 May 15.

PMID:
19448065
[PubMed - indexed for MEDLINE]
19.

Predicting axillary sentinel node status in patients with primary breast cancer.

Kolarik D, Pecha V, Skovajsova M, Zahumensky J, Trnkova M, Petruzelka L, Halaska M, Sottner O, Otcenasek M, Kolarova H.

Neoplasma. 2013;60(3):334-42. doi: 10.4149/neo_2013_045.

PMID:
23374005
[PubMed - indexed for MEDLINE]
20.

Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.

Nogi H, Suzuki M, Kamio M, Kato K, Kawase K, Toriumi Y, Takeyama H, Fukushima H, Morikawa T, Uchida K.

Oncol Rep. 2011 Apr;25(4):1109-15. doi: 10.3892/or.2011.1177. Epub 2011 Feb 9.

PMID:
21308353
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk